Charu Aggarwal, MD

Articles

Next Steps in Managing Chemo-Induced Myelosuppression

September 16th 2021

Trials of interest exploring various novel therapies as chemoprotection in patients with solid tumor cancers.

Expanded Access to Trilaciclib for Patients With ES-SCLC

September 16th 2021

Jared Weiss, MD, reacts to new measures that increase patient access and provider reimbursement to trilaciclib for patients with extensive-stage small cell lung cancer.

Limitations When Managing Chemo-Induced Myelosuppression

September 2nd 2021

Pros and cons of strategies used to manage chemotherapy-induced myelosuppression in extensive-stage small cell lung cancer.

Clinical Impact of Chemo-Induced Myelosuppression in ES-SCLC

August 26th 2021

Drs Charu Aggarwal and Jared Weiss react to the impact that chemotherapy-induced myelosuppression can have on patients with extensive-stage small cell lung cancer, as well as the overall health system.

Chemo-Induced Myelosuppression in ES-SCLC

August 26th 2021

Types of chemotherapy-induced myelosuppression that typically occur in patients with extensive-stage small cell lung cancer and considerations for treating patients based on risk factors and presentation of adverse events.

Dr. Aggarwal on Investigational Biomarkers in Lung Cancer

October 16th 2020

Charu Aggarwal, MD, MPH, discusses investigational biomarkers in lung cancer.

Dr. Aggarwal on Emerging Treatment Approaches in ALK+ NSCLC

July 23rd 2020

Charu Aggarwal, MD, MPH, discusses emerging treatment approaches in ALK-positive non–small cell lung cancer.

Dr. Aggarwal on Triplet Therapy in EGFR-Mutant Lung Cancer

July 27th 2018

Charu Aggarwal, MD, assistant professor of Medicine, University of Pennsylvania, discusses triplet therapy in EGFR-mutant lung cancer.

Moving Forward in Head and Neck Squamous Cell Cancer

January 25th 2018

Development of effective therapies for metastatic head and neck cancer has been challenging, and progress has been slow.